ATRC logo

ATRC

AtriCure Inc.

$36.17
+$2.92(+8.78%)
42
Overall
60
Value
25
Tech
--
Quality
Market Cap
$1.80B
Volume
571.22K
52W Range
$28.29 - $43.11
Target Price
$51.44

Company Overview

Mkt Cap$1.80BPrice$36.17
Volume571.22KChange+8.78%
P/E Ratio-40.2Open$33.31
Revenue$465.3MPrev Close$33.25
Net Income$-44.7M52W Range$28.29 - $43.11
Div YieldN/ATarget$51.44
Overall42Value60
Quality--Technical25

No chart data available

About AtriCure Inc.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Sector: Healthcare
Industry: Medical Instruments & Supplies

Latest News

Stifel Nicolaus Keeps Their Buy Rating on Atricure (ATRC)

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Atricure, with a price target of $50.00. The company’s shares...

TipRanks Auto-Generated Intelligence Newsdesk25 days ago

AtriCure’s Ongoing Study: Implications for Cardiac Treatment and Market Performance

TipRanks Clinical-Trials-Auto-Generated Newsdeska month ago

AtriCure’s Cryoablation Study: A New Frontier in Pain Management

TipRanks Clinical-Trials-Auto-Generated Newsdeska month ago
ABCD
1SymbolPriceChangeVol
2ATRC$36.17+8.8%571.22K
3
4
5
6

Get AtriCure Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.